PharmaCorp Rx Inc.
PharmaCorp Rx Inc. operates retail pharmacies under the PharmaChoice name in Canada. It offers prescription drug and custom compounding specialization services; weight loss and lifestyle management solutions, including health and wellness products; and convenience and confectionary products. The company was incorporated in 2021 and is headquartered in Saskatoon, Canada.
Market Cap & Net Worth: PharmaCorp Rx Inc. (PCRX)
PharmaCorp Rx Inc. (V:PCRX) has a market capitalization of $35.70 Million (CA$51.27 Million) as of March 18, 2026. Listed on the V stock exchange, this Canada-based company holds position #23467 globally and #112 in its home market, demonstrating a 1.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaCorp Rx Inc.'s stock price CA$0.43 by its total outstanding shares 119226659 (119.23 Million).
PharmaCorp Rx Inc. Market Cap History: 2025 to 2026
PharmaCorp Rx Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $37.77 Million to $35.70 Million (0.00% CAGR).
PharmaCorp Rx Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaCorp Rx Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PCRX by Market Capitalization
Companies near PharmaCorp Rx Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to PharmaCorp Rx Inc. by market ranking:
- Alibaba Health Information Technology Limited (PINK:ALBBY): Ranked #1435 globally with a market cap of $12.50 Billion USD.
- Walgreens Boots Alliance Inc (NASDAQ:WBA): Ranked #1880 globally with a market cap of $8.58 Billion USD.
- Raia Drogasil S.A (SA:RADL3): Ranked #2749 globally with a market cap of $5.08 Billion USD ( R$30.91 Billion BRL).
- Clicks Group Ltd (PINK:CLCGY): Ranked #2859 globally with a market cap of $4.80 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1435 | Alibaba Health Information Technology Limited | PINK:ALBBY | $12.50 Billion | $12.32 |
| #1880 | Walgreens Boots Alliance Inc | NASDAQ:WBA | $8.58 Billion | $11.98 |
| #2749 | Raia Drogasil S.A | SA:RADL3 | $5.08 Billion | R$23.58 |
| #2859 | Clicks Group Ltd | PINK:CLCGY | $4.80 Billion | $35.11 |
PharmaCorp Rx Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, PharmaCorp Rx Inc.'s market cap moved from $37.77 Million to $ 35.70 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$35.70 Million | -5.49% |
| 2025 | CA$37.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PharmaCorp Rx Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.70 Million USD |
| MoneyControl | $35.70 Million USD |
| MarketWatch | $35.70 Million USD |
| marketcap.company | $35.70 Million USD |
| Reuters | $35.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.